The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track designation for PET ...

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort. While the rate of ureteral strictures following ureteroscopic laser lithotripsy is low, the incidence ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

Current 2025 guidelines recommend ADT with intensification. Multiple intensification options include abiraterone, darolutamide, and docetaxel. Key clinical trials include ARANOTE, ARASENS, and TITAN.

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD. “This was a multi-institutional study, and the goal was to evaluate the urologist ...

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

Masses under 2 cm are typically managed with active surveillance. Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches. Kidney ...

The first successful human bladder transplant was performed by USC and UCLA surgeons, marking a significant medical milestone. The patient, previously on dialysis, showed immediate improvement ...

The phase 3 study design will now be submitted for final review by the agency. Promontory Therapeutics Inc has reported a positive end of phase 2 (EOP2) meeting with the FDA, paving the way for the ...

Genomic alteration frequencies differ between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but survival outcomes are similar. Non-Hispanic Black patients have ...

Black men are significantly underrepresented in prostate cancer clinical trials (<5% in most studies). Many trials fail to provide race-specific data. The ARANOTE study achieved 10% representation of ...

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes. Dr Shore presented data demonstrating that ...